Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00678054
Recruitment Status : Completed
First Posted : May 15, 2008
Last Update Posted : August 23, 2017
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
This is a Phase II study to test the efficacy of exogenously administered GM-CSF in prostate cancer patients who have failed definitive local therapy, and have only serologic (PSA) evidence of progression.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: GM-CSF Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment of Patients With Evidence of Serologic (PSA) Progression After Definitive Therapy for Localized Prostate Cancer
Study Start Date : April 1999
Actual Primary Completion Date : August 11, 2000
Actual Study Completion Date : October 23, 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Drug: GM-CSF
Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.

Primary Outcome Measures :
  1. PSA Response [ Time Frame: Monthly ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic diagnosis of adenocarcinoma of the prostate; stage T1-T3, N0-N1, M0
  • Prior definitive therapy for primary prostate cancer consisting of:external beam radiotherapy;brachytherapy with or without pelvic external beam radiation; or radical prostatectomy with or without adjuvant or salvage radiation therapy
  • Therapeutic PSA response to primary therapy below 1.0 ng/ml post radiation therapy or below 0.4 ng/ml for radical prostatectomy
  • Patients treated with adjuvant or salvage radiation therapy following radical prostatectomy are eligible provided:Post prostatectomy PSA was never > 6.0 ng/ml, last effective day of androgen deprivation is at least 3 months prior to study entry
  • Recurrent PSA level elevation (between 0.4 ng/ml and 6.0 ng/ml) on two determinations at least one week apart.
  • No clinical evidence of gross local recurrence or known metastatic disease other than PSA elevation. Transrectal ultrasound and/or biopsy to evaluate local recurrence is not required. All patients will receive a bone scan and CT scan of the abdomen to exclude metastases.
  • Estimated life expectancy of at least 6 months.
  • ECOG Performance status of 0 or 1.
  • Willing and able to give informed consent.

Exclusion Criteria:

  • Cryosurgery as definitive therapy of primary tumor.
  • Any metastasis.
  • No concurrent or prior malignancy is allowed except for the following: adequately treated basal or squamous cell skin cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.
  • Current systemic steroid therapy (inhaled or topical steroids acceptable).
  • Prior hormonal therapy for treatment of progressive disease.
  • Prior chemotherapy, immunotherapy, or therapy with other experimental agents for prostate cancer.
  • Any surgery within the prior 4 weeks.
  • Bilirubin and SGOT > 2 x upper limit of normal.
  • BUN and serum creatinine > 2.0 times normal.
  • No active congestive heart failure.
  • If there is a history of clinically significant obstructive airway disease, a DLCO must exceed 50%.
  • Active uncontrolled bacterial, viral or fungal infection until these conditions are corrected or controlled.
  • Any underlying medical condition which in the principal investigator's opinion will make the administration of GM-CSF hazardous or obscure the interpretation of adverse events.
  • PSA > 6.0 ng/ml

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00678054

United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
Sponsors and Collaborators
University of California, San Francisco
Principal Investigator: Eric Small, MD University of California, San Francisco

Publications of Results:
Responsible Party: University of California, San Francisco Identifier: NCT00678054     History of Changes
Other Study ID Numbers: UCSF99551
First Posted: May 15, 2008    Key Record Dates
Last Update Posted: August 23, 2017
Last Verified: August 2017

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases